Lobbying Information
Subject Matters
- Consumer Issues
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Science and Technology
- Small Business
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic Trade Agreement with respect to pharmaceuticals, counterfeit medicines, border measures, and intellectual property.
Policies or Program
- Innovation, Science and Economic Development Canada's Science & Technology strategy regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
- Patented Medicine Prices Review Board regarding claims of jurisdiction with respect to generic drug products associated with a patent.
- Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
- Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions
- Provide input into guidance with respect to the process for the approval and renewal of foreign sites for Drug Establishment License (DEL) holders.
- Provide input into policy discussions regarding the potential development of a national pharmacare program governments.
- Providing input into the development and implementation of an approval pathway for Subsequent Entry Biologics by Health Canada.
- To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat counterfeit pharmaceutical both nationally and globally.
- participation in consultations, providing comments on modernization of the Food and Drugs Act and related regulations regarding pharmaceuticals
Regulation
- The need for amendments to the Patented Medicines (Notice of Compliance) Regulations of the Patent Act and address operational concerns such as bringing finality to proceedings under the Regulations; allowing generic manufacturers to amend a Notice of Allegation; and providing meaningful damages and other disincentives to discourage abuse of the Regulatioins by brand name manufacturers.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Canadian International Trade Tribunal (CITT)
-
Finance Canada (FIN)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Provider of generic and specialty pharmaceuticals.
Responsible officer name and position during the period of this registration
Barry Hayter,
Country Manager - Mylan Canada
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
85 Advance Road
Etobicoke, ON M8Z 2S6
Canada
Telephone number:
416-207-1623
Parent Company Information
Mylan Pharmaceuticals ULC is not a subsidiary of any other parent companies.
Subsidiary Beneficiary Information
Mylan Pharmaceuticals ULC does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Barry Hayter,
Country Manager |
No public offices held
- Joanne Manley,
Director, Regulatory Affairs |
No public offices held
- Bonnie Southorn,
Director, Regulatory Affairs |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
No lobbyists added